Journey Medical reports Q1 EPS 2c vs. (4c) last year

Reports Q1 revenue $15.96M, consensus $15.48M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “2026 is off to a strong start, as we delivered solid revenue growth and cash generation in the first quarter of the year. Prescription demand and payer coverage for Emrosi continue to increase, with the product’s differentiated clinical profile gaining traction as we establish Emrosi as the best-in-class oral treatment for patients suffering from rosacea. Increasing refill rates and a growing number of Emrosi prescribers are also building momentum behind the brand. Our net product sales growth in the quarter coupled with disciplined investment in our dermatology-focused commercial infrastructure resulted in improved operating leverage, and we expect this trend to continue going forward. With over $27 million in cash and Emrosi(R) entering its second year on the market, we remain well-positioned to continue to execute on our strategy and deliver strong financial progress throughout the year.”